Clinical Trials Browser

Phase 2 × Neoplasms, Second Primary × Panitumumab × Clear all

NCT04034173 2019-07-26

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Phase 2 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasms, Second Primary